OBJECTIVE:To probe into the clinical efficacy of salmeterol and budesonide respectively combined with montelukast sodium in the treatment of cough variant asthma（CVA）and its effects on related indicators.METHODS:A total of 90 patients with CVA admitted into the Second Hospital of Shijiazhuang and the Fifth Hospital of Shijiazhuang in 2018 were extracted to be divided into the salmeterol group

the budesonide group and the control group via the random number table

with 30 cases in each group.Patients in the salmeterol group were treated with salmeterol and montelukast sodiumt

the budesonide group was given budesonide and montelukast sodium

and the control group received budesonide alone.All patients were treated for 3 months.The clinical efficacy

cough symptom scores

serum levels of interleukin-2（IL-2）

interleukin-4（IL-4）

tumor necrosis factor-α（TNF-α）

immunoglobulin E（IgE）

serum amyloid A（SAA）

transforming growth factor-β1（TGF-β1）and pulmonary function indicators[forced expiratory volume（FEV

1

）

maximum expiratory flow（PEF）and FEV

1

/forced vita capacity（FVC）at the end of the 1st second]of three groups were observed

differences of incidence of adverse drug reactions were compared.RESULTS:The total effective rates of the salmeterol group and the budesonide group were96.67%（29/30）and 90.00%（27/30）

significantly higher than 73.33%（22/30）of the control group

the difference was statistically significant（P

<

0.05）.After treatment of one week

the scores of daytime cough symptom and nighttime cough symptom in the salmeterol group and budesonide group were significantly lower than those in the control group

the difference was statistically significant（P

<

0.05）.After treatment of two weeks

there was no significant difference in scores of daytime cough symptom and nighttime cough symptom among three groups（P

>

0.05）.After treatment

the levels of IL-4

TNF-α

IgE

SAA and TGF-β1 in three groups were significantly lower than those before treatment

and the levels of IL-2 were significantly higher than those before treatment

with statistically significant differences（P

<

0.05）.After treatment

the levels of IL-4

TNF-α

IgE

SAA and TGF-β1 in the salmeterol group and the budesonide group were significantly lower than those in the control group

and the levels of IL-2 were significantly higher than those in the control group

with statistically significant differences（P

<

0.05）After treatment

the levels of FEV

1

PEF and FEV

1

/FVC in three groups were significantly higher than those before treatment

the salmeterol group and the budesonide group were significantly higher than the control group

with statistically significant differences（P

<

0.05）.The improvement of serum levels of IL-4

IL-2

TNF-α

IgE

SAA and TGF-β1 and pulmonary function indicators in the salmeterol group was better than that in the budesonide group

ye the difference was not statistically significant（P

>

0.05）.There was no statistically significant difference in the incidence of adverse drug reactions among three groups（χ

2

=2.069

P=0.355）.CONCLUSIONS:Salmetero combined with montelukast sodium and budesonide combined with montelukast in the treatment of patients with CVA can alleviate the inflammation of the patients

thereby effectively improving the pulmonary function and improving the clinical efficacy.